exe-346
Cell therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 11, 2023 (NCT05938465)
Timeline
Indications
Mechanism of action
- microbiotaTissue restoration
microbiota tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06949800 | Phase 2 | Dec 1, 2025 | Exegi Pharma, LLC, National Cancer Institute (NCI), University of California, San Francisco |
| NCT05938465 | Phase 1/Phase 2 (Phase 2) | Oct 11, 2023 | Exegi Pharma, LLC, The EMMES Corporation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Exegi Pharma, LLC | For profit | 2 | 1 | 1 | 2023 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2025 |
| The EMMES Corporation | For profit | 1 | 0 | 1 | 2023 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1